Clinical trials: CD - Crohn's Disease
Crohn's Disease
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
- Trial name
- CD04 (NCT00739986)
- Testing
- Semapimod
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 152 people
- Sponsor
- Ferring Pharmaceuticals
Crohn Disease (CD)
Health Benefits of Tart Cherry in Crohn's Disease
Crohn's disease (CD) is a long-term inflammatory condition of the digestive tract. People with CD often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue.
- Trial name
- NCT06901986
- Testing
- Montmorency tart cherry
- Volunteers
- 52 people
- Sponsor
- University of Central Lancashire
Crohn Disease
Biologics and Partial Enteral Nutrition Study
Crohn's disease (CD) is a chronic, incurable condition associated with inflammation in the gut lining. It causes diarrhoea, severe abdominal pain, poor nutrition and adversely affects the quality of life of sufferers.
- Trial name
- BIOPIC (NCT04859088)
- Testing
- Partial Enteral Nutrition
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Crohn's Disease, Ulcerative Colitis
The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients
Inflammatory Bowel Diseases (IBD) are life-long, incurable illnesses that can have a profound effect on the patients quality of life.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Anxiety
- Trial name
- NCT01916161
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 307 people
- Sponsor
- National Health Service, United Kingdom
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
The SHIFT-IBD Study is being conducted at multiple medical centers across Canada to evaluate how well guselkumab (Tremfya) works for people with inflammatory bowel disease (IBD) who haven't responded well enough to ustekinumab.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC), IBD-unclassified (IBD-U)
- Trial name
- SHIFT-IBD (NCT07245394)
- Testing
- Guselkumab (Tremfya)
- Where
- 14 sites in Canada
- Volunteers
- 200 people
- Sponsor
- TIDHI Innovation Inc.
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD)
Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic immune-mediated disorder requiring long-term management.
- Conditions
- Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Crohn's Disease (CD), Ulcerative Colitis (UC), Artificial Intelligence (AI)
- Trial name
- NCT07590271
- Where
- Taiwan
- Volunteers
- 4,500 people
- Sponsor
- Taichung Veterans General Hospital
Ulcerative Colitis, Crohn Disease
Microbial and Human Determinants of the Onset of IBD Flares
This is a longitudinal, observational study that aims to identify the microbial and human molecular triggers of IBD flares via stool, saliva, and blood metatranscriptomes, whole blood proteome, and collected clinical metadata.
- Conditions
- Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated
- Trial name
- NCT05463900
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Viome
Crohn's Disease
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for…
- Trial name
- NCT03395184
- Testing
- PF-06651600, PF-06700841
- Where
- 195 sites in United States, Australia and 24 more
- Volunteers
- 244 people
- Sponsor
- Pfizer
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Crohn's Disease, Ulcerative Colitis
Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease
The primary objective of this study is to evaluate sustained clinical remission (for the definition see below) in patients with inflammatory bowel disease receiving long-term (> 2 years) scheduled treatment with infliximab.
- Trial name
- NCT02057016
- Where
- Italy
- Volunteers
- 258 people
- Sponsor
- Catholic University of the Sacred Heart
Pouch, Ileal, Fistula
Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease
The purpose of this study is to determine the safety and feasibility of using Ossium vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC) to treat people with an ileal pouch anal anastomosis (IPAA) who develop a fistula…
- Trial name
- NCT05075811
- Testing
- Ossium vBM-MSC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Anthony Lembo
Inflammatory Bowel Diseases
Azathioprine Linked With Impaired Intestinal Epithelial Postoperative Regeneration in Crohn's Disease
What is known? the impact of AZA, immunomodulatory drug widely used in active CD, on the intestinal wall differs from those of steroids, what is reflected in the significant difference in the postoperative anastomotic leaks rate…
- Trial name
- NCT05456776
- Volunteers
- 35 people
- Sponsor
- Centre of Postgraduate Medical Education
Crohn's Disease
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
180 patients suffering from active Crohn's disease with evidence of mucosal ulceration will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 or matching placebo once daily for 20 weeks in addition…
- Trial name
- NCT02048618
- Testing
- GLPG0634
- Where
- 63 sites in Belgium, Czechia and 7 more
- Volunteers
- 175 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn's Disease
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059…
- Trial name
- COSPAR II (NCT00356408)
- Testing
- Certolizumab pegol
- Where
- 63 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- UCB Pharma
Crohn Disease
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy
INTRODUCTION: Vedolizumab is a gut selective anti-integrin agent which binds to the alfa4beta7 integrin, preventing its coupling to the endothelial MadCAM-1.
- Trial name
- NCT04362735
- Testing
- Vedolizumab
- Volunteers
- 100 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Inflammatory Bowel Diseases
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
This phase will commence following dose escalation in the 24mg bid group during Phase I. Employing a 1:1:1 randomized, double-blind, placebo-controlled study design, it will evaluate the efficacy, safety, and…
- Trial name
- NCT06754891
- Testing
- 24mg bid TQH3906 capsule, 32mg TQH3906 capsule
- Where
- 30 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Moderately to Severely Active Crohns Disease
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with…
- Trial name
- SIBERITE-1 (NCT06819878)
- Testing
- Afimkibart
- Where
- 375 sites in United States, Argentina and 36 more
- Volunteers
- 600 people
- Sponsor
- Hoffmann-La Roche
Healthy
Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People
This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people.
- Trial name
- NCT01162889
- Testing
- ATR-107 (PF-05230900) SC Injection, ATR-107 (PF-05230900) IV Infusion
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Pfizer
Inflammatory Bowel Diseases
Based on the Special Disease Management of Crohn's Disease Diet Studies
This project plans to develop a new diet therapy suitable for China -- CD-C-food, which is more in line with the common diet of Chinese patients' eating habits and economic conditions, and its expected therapeutic effect and…
- Trial name
- NCT04976491
- Testing
- CD-C-Food, EEN
- Where
- China
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Crohn's Disease
Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease
The purpose of this study for children with a new diagnosis of Crohn's disease is to identify biomarkers found in the blood or stool to help predict which children are at risk of developing complications.
- Trial name
- RS (NCT00790543)
- Where
- 28 sites in United States, Canada
- Volunteers
- 1,813 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.